About the Council
The Healthcare Council highlights the potential of new biotechnology solutions, the pipeline of their applications and defines the implications these new tools will have on the European regulatory and legislative framework.
New advances in biological sciences combined with the acceleration of computing, data processing and artificial intelligence are transforming how healthcare is delivered to patients.
The Healthcare Council develops proposals in areas significantly impacted by this new wave of innovation: cell and gene therapies, medicines for rare diseases and children, data and digital, regulatory efficiencies, biosimilars and procurement.
The Council also delivers the Patient Bio-Forum as the platform of exchange of views between patient organisations and healthcare biotechnology members.
The Council works through three Council meetings per year, supported by Working Groups across priority topics.
The Healthcare Biotechnology Council has priorities selected by Members for shared work throughout the year, delivered through working groups and Council meetings. Priorities include:
Medicines for Rare Diseases & Children
Encouragement is needed for investment into Research & Development for rare diseases currently suffering from lack of treatment or unmet need. EuropaBio places particular attention on working with public authorities to discuss patient access to novel, often advanced, treatments created by the research to date.
Awareness raising is critical for the transformative impact of cell and gene therapies for patients and society. Healthcare systems also need adaptation to ensure that patients across the EU can fully benefit from such therapeutics.
This priority underpins many EuropaBio activities. The input and views from patient organisations on scientific, regulatory and policy issues actively sought and integrated, to enable better support for EuropaBio contributions to the healthcare policy debate in the EU. The Patient BioForum is at the centre of this priority.
Digital healthcare advances
This is an increasing priority for EuropaBio, addressing how the digital revolution will affect healthcare, including improvement of the R&D for new diagnostics and treatments for illnesses.
EuropaBio seeks a progressive regulatory framework for efficient uptake of new healthcare biotechnologies in the EU. We actively engage in the implementation of the European Health Union, the EU Pharmaceutical Strategy, as well as in the EMA and HMA regulatory strategies with a view to support speed, innovation and EU competitiveness.
Biosimilars & Public Procurement
The final priority for the Healthcare Council, sees EuropaBio advocating for a high standard of clinical evidence before issuing any new medicine to a patient, and supporting public procurement as a means of improving patient access to innovative medicines.
The Healthcare Biotechnology Council has priorities selected by Members for shared work throughout the year, delivered through working groups and Council meetings. Priorities in 2021 include: